U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Financial Disclosure by Clinical Investigators
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Financial Disclosure by Clinical Investigators Guidance for Clinical Investigators, Industry,and FDA Staff February 2013

Download the Final Guidance Document
Final
Docket Number:
FDA-1999-D-0742
Issued by:
Guidance Issuing Office
Office of the Commissioner, Office of Clinical Policy and Programs, Office of Clinical Policy, Office of Good Clinical Practice
Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

This guidance is intended to assist clinical investigators, industry, and FDA staff in interpreting and complying with the regulations governing financial disclosure by clinical investigators, 21 CFR part 54.  This document is a revision of the Guidance for Industry: Financial Disclosure by Clinical Investigators dated March 20, 2001.  In order to address issues raised by the Office of the Inspector General (OIG), Department of Health and Human Services, in its report, OEI-05-07-00730, The Food and Drug Administration’s Oversight of Clinical Investigators’ Financial Information as well as questions FDA has received from industry and the public, FDA issued a revised guidance in draft in May 2011 for public comment.  Comments were received from 13 individuals and entities, which were considered in preparing this final guidance.  FDA encourages applicants and sponsors to contact the agency for advice concerning specific circumstances regarding financial disclosures that may raise concerns as early in the product development process as possible. 

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-1999-D-0742.

Back to Top